drugset / Trial / NCT02650063

A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -

NCT02650063

Phase 1 Completed 14 enrolled Santen Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelBasic science

Summary

The purposes of this study are to evaluate the safety and plasma pharmacokinetics of DE-117 ophthalmic solution (one drop once daily for 7 days) in healthy male adults.

Timeline

Start
2015-12
Primary completion
2016-02
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject omidenepag isopropyl Small molecule Other

Indications

No indication recorded.